Jazz Pharmaceuticals (JAZZ) posted Q1 non-GAAP earnings late Tuesday of $1.68 per diluted share, down from $2.63 a year ago.
Analysts polled by FactSet expected $4.66.
Revenue for the quarter ended March 31 was $897.8 million, down from $902.0 million a year earlier.
Analysts surveyed by FactSet expected $983.8 million.
For 2025, the company said it now expects adjusted EPS of $4.00 to $5.60 on revenue of $4.15 billion to $4.40 billion.
It forecast EPS of $22.50 to $24.00 previously. Analysts expected $23.22 and $4.29 billion, respectively.
Shares of Jazz were down about 6.5% in after-hours activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。